Spinal cannabinoids are anti-allodynic in rats with persistent inflammation

Pain

Volumn 82, Issue 2, 1999, Pages 199-205

  Martin, William J ^a   Loo, Carole M ^a   Basbaum, Allan I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allodynia; Inflammation; Spinal cannabinoids

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID RECEPTOR; FORMALDEHYDE; FREUND ADJUVANT; RIMONABANT;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INFLAMMATION; INTRATHECAL DRUG ADMINISTRATION; MALE; NONHUMAN; ONCOGENE C FOS; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; SPINAL CORD; SPINAL CORD DORSAL HORN; SPINAL CORD VENTRAL HORN;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; CANNABINOIDS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SPINAL; MALE; MORPHOLINES; NAPHTHALENES; NERVE TISSUE PROTEINS; NEURITIS; PAIN THRESHOLD; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-FOS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; STRESS, MECHANICAL;

EID: 0033027735     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(99)00045-7     Document Type: Article

References (44)

1. Besson J.M., Chaouch A. Peripheral and spinal mechanisms of nociception. Physiol Rev. 67:1987;67-186.
2. Bloom A.S., Dewey W.L., Harris L.S., Brosius K.K. 9-nor-9beta-hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine, J Pharmacol Exp Ther. 200:1977;263-270.
3. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1.Evidence for a new model of receptor/ligand interactions. J Biol Chem. 272:1997;22330-22339.
4. Buxbaum D.M. Analgesic activity of 9-tetrahydrocannabinol in the rat and mouse. Psychopharmacology (Berl). 25:1972;275-280.
5. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
6. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 53:1994;55-63.
7. D'Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., Haycock D.A., Baizman E.R., Casiano F.M., Beglin N.C., Chippari S.M., Grego J.D., Kullnig R.K., Daley G.T. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem. 35:1992;124-135.
8. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor (see comments). Science. 258:1992;1946-1949.
9. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons (see comments). Nature. 372:1994;686-691.
10. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol. 231:1993;313-314.
11. Friedel R.H., Schnurch H., Stubbusch J., Barde Y.A. Identification of genes differentially expressed by nerve growth factor- and neurotrophin-3-dependent sensory neurons. Proc Natl Acad Sci USA. 94:1997;12670-12675.
12. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 11:1991;563-583.
13. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 221:1997;157-160.
14. Hohmann A.G., Briley E.M., Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu receptors in rat spinal cord. Brain Res. 822:1999;17-25.
15. Hohmann A.G., Herkenham M. Localization of cannabinoid receptor (CB1) mRNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 90:1999;923-931.
16. Hohmann A.G., Martin W.J., Tsou K., Walker J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56:1995;2111-2118.
17. Hsu S.M., Raine L. Protein A, avidin, and biotin in immunocytochemistry. J Histochem Cytochem. 29:1981;1349-1353.
18. Jacob J.J., Ramabadran K., Campos-Medeiros M. A pharmacological analysis of levonantradol antinociception in mice. J Clin Pharmacol. 21:1981;327S-333S.
19. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol. 334:1997;R1-R2.
20. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther. 258:1991;517-523.
21. Llewellyn-Smith I.J., Minson J.B. Complete penetration of antibodies into vibratome sections after glutaraldehyde fixation and ethanol treatment: light and electron microscopy for neuropeptides. J Histochem Cytochem. 40:1992;1741-1749.
22. Ma Q.P., Woolf C.J. Basal and touch-evoked fos-like immunoreactivity during experimental inflammation in the rat. Pain. 67:1996;307-316.
23. MacLennan S.J., Reynen P.H., Kwan J., Bonhaus D.W. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors (in process citation). Br J Pharmacol. 124:1998;619-622.
24. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects, J Neurosci. 16:1996;6601-6611.
25. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA (see comments). Nature. 346:1990;561-564.
26. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesia circuit activated by cannabinoids. Nature. 395:1998;381-383.
27. Mestre C., Pelissier T., Fialip J., Wilcox G., Eschalier A. A method to perform direct transcutaneous intrathecal injections in rats. J Pharmacol Toxicol Methods. 32:1994;197-200.
28. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Ann Rev Neurosci. 14:1991;421-451.
29. Moss D.E., Johnson R.L. Tonic analgesic effects of delta 9-tetrahydrocannabinol as measured with the formalin test. Eur J Pharmacol. 61:1980;313-315.
30. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids (see comments). Nature. 365:1993;61-65.
31. Richardson J.D., Aanonsen L., Hargreaves K.M. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol. 319:1997;R3-R4.
32. Richardson J.D., Aanonsen L., Hargreaves K.M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci. 18:1998a;451-457.
33. Richardson J.D., Aanonsen L., Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 345:1998b;145-153.
34. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 75:1998c;111-119.
35. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
36. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci. 16:1996;4322-4334.
37. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther. 270:1994;219-227.
38. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav. 60:1998;183-191.
39. Sofia R.D., Nalepa S.D., Harakal J.J., Vassar H.B. Anti-edema and analgesic properties of delta9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther. 186:1973;646-655.
40. Tsou K., Lowitz K.A., Hohmann A.G., Martin W.J., Hathaway C.B., Bereiter D.A., Walker J.M. Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70:1996;791-798.
41. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
42. Welburn P.J., Starmer G.A., Chesher G.B., Jackson D.M. Effects of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacology (Berl). 46:1976;83-85.
43. Willis W.D., Coggeshall R.E. Sensory mechanisms of the spinal cord, 2nd edn. 1991;Plenum Press, New York.
44. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.